India's pharma and life sciences sector is undergoing a significant shift towards innovation, driven by a convergence of enablers including government funding, evolving academic-industry linkages, regulatory reforms, and the development of shared research and manufacturing infrastructure. This momentum is reflected in the doubling of patent filings, growth in innovation pipeline assets, and increased biotech startups and private capital investment. However, India's innovation landscape remains nascent compared to global peers, with R&D spend and clinical trial participation significantly lower. The report identifies three key arenas where India holds a structural advantage: cost-disruptive innovation, India-specific biology and data for precision medicine, and science-driven platform innovation. Companies are pursuing multiple innovation pathways, including late-stage in-licensing, India-first validation, global-first innovation, academic spin-outs, and pure-play biotech platforms. Despite these strengths, structural gaps persist, particularly in access to early-stage patient capital, bench-to-bedside translation from academia, and execution gaps in clinical trial infrastructure, regulatory capacity, and domestic supply chains. The report concludes that India has the potential to become a global innovation originator, but this will require focused execution, patient capital, and coordinated action across the ecosystem to address these gaps. Key initiatives to determine India's innovation decade include creating fast-track regulatory pathways for novel therapies, building domestic supply chains, and bridging the talent quality gap in R&D and innovation.
